{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:17:11Z","timestamp":1786119431305,"version":"build-2736575974"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1097\/wnf.0b013e3181dca96f","type":"journal-article","created":{"date-parts":[[2010,4,8]],"date-time":"2010-04-08T02:53:47Z","timestamp":1270695227000},"page":"207-208","source":"Crossref","is-referenced-by-count":4,"title":["Treatment of Benign Essential Blepharospasm With Finasteride"],"prefix":"10.1097","volume":"33","author":[{"given":"Marco","family":"Bortolato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Cannas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Solla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Puligheddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Muroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Marrosu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210203","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1212\/01.wnl.0000327601.46315.85","article-title":"Update on blepharospasm: report from the BEBRF International Workshop.","volume":"71","author":"Hallett","year":"2008","journal-title":"Neurology"},{"key":"R2-9-20210203","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/archopht.1985.01050030043017","article-title":"Botulinum A toxin injection as a treatment for blepharospasm.","volume":"103","author":"Scott","year":"1985","journal-title":"Arch Ophthalmol"},{"key":"R3-9-20210203","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/mds.870100407","article-title":"The blepharospasm disability scale: an instrument for the assessment of functional health in blepharospasm.","volume":"10","author":"Lindeboom","year":"1995","journal-title":"Mov Disord"},{"key":"R4-9-20210203","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.yhbeh.2005.11.003","article-title":"Self-administration of estrogen and dihydrotestosterone in male hamsters.","volume":"49","author":"DiMeo","year":"2006","journal-title":"Horm Behav"},{"key":"R5-9-20210203","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1136\/jnnp.67.5.613","article-title":"Risk factors for spread of primary adult onset blepharospasm: a multicentre investigation of the Italian movement disorders study group.","volume":"67","author":"Defazio","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R6-9-20210203","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s004150050347","article-title":"Idiopathic blepharospasm does not lead to a parkinsonian syndrome: results of a questionnaire-based follow-up study.","volume":"246","author":"Soonawala","year":"1999","journal-title":"J Neurol"},{"key":"R7-9-20210203","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1055\/s-2008-1058110","article-title":"Improvement of general symptoms in a chronic psychotic patient treated with finasteride: case report.","volume":"41","author":"Koethe","year":"2008","journal-title":"Pharmacopsychiatry"},{"key":"R8-9-20210203","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1176\/appi.ajp.2007.07060978","article-title":"Treatment of Tourette's syndrome with finasteride.","volume":"164","author":"Bortolato","year":"2007","journal-title":"Am J Psychiatry"},{"key":"R9-9-20210203","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1176\/jnp.2006.18.4.554","article-title":"Essential blepharospasm responding to haloperidol.","volume":"18","author":"Bhatia","year":"2006","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"R10-9-20210203","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1159\/000054375","article-title":"Seizure activity is increased in endocrine states characterized by decline in endogenous levels of the neurosteroid 3 alpha,5alpha-THP.","volume":"68","author":"Frye","year":"1998","journal-title":"Neuroendocrinology"},{"key":"R11-9-20210203","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.yhbeh.2007.04.006","article-title":"Acute effects of neurosteroids in a rodent model of primary paroxysmal dystonia.","volume":"52","author":"Hamann","year":"2007","journal-title":"Horm Behav"},{"key":"R12-9-20210203","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1038\/npp.2008.39","article-title":"Antipsychotic-like properties of 5-alpha-reductase inhibitors.","volume":"33","author":"Bortolato","year":"2008","journal-title":"Neuropsychopharmacology"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00002826-201007000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:13:33Z","timestamp":1786040013000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002826-201007000-00009"}},"subtitle":["A Case Report"],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e3181dca96f","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}